Browse Studies — Arctuva

Phase 1

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (ad…

Cutaneous Squamous Cell CarcinomaSCC - Squamous Cell CarcinomaBasal Cell Carcinoma+16 more

Estimated

~$10 – $6,250

Find your next paid study

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Prospective Registry of Gynecologic Patients With Extramammary Paget's Disease